Concomitant tumor resistance: The role of tyrosine isomers in the mechanisms of metastases control

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1043-1050

  Ruggiero, Raúl A ^a   Bruzzo, Juan ^a   Chiarella, Paula ^a   Bustuoabad, Oscar D ^a   Meiss, Roberto P ^a   Pasqualini, Christiane D ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXYPHENYL)ALANINE; CYCLIN DEPENDENT KINASE 1; META TYROSINE; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; TRANSFER RNA;

AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; CANCER INHIBITION; CELL CYCLE G0 PHASE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; METASTASIS INHIBITION; METASTASIS POTENTIAL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; S PHASE CELL CYCLE CHECKPOINT; SERUM FACTOR; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; TUMOR VASCULARIZATION;

ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; NEOPLASMS; S PHASE; STAT3 TRANSCRIPTION FACTOR; TYROSINE;

EID: 84857715047     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2964     Document Type: Review

References (69)

1. Ehrlich P. Experimentelle Carcinomstudien an mausen. Arb Inst Exp Ther Frankfurt 1906;1:77-103.
2. Bashford E, Murray J, Haaland M. General results of propagation of malignant new growths. In:Bashford E, editor. Third scientific report on the investigation of the Imperial Cancer Research Fund. Vol. 3. London: Taylor and Francis; 1908. p. 262-8.
3. Woglom WH. Immunity to transplantable tumors. Cancer Rev 1929;4:129-209.
4. Southam CM. Host defense mechanisms and human cancer. Ann Inst Pasteur (Paris) 1964;107:585-97.
5. Brunschwig A, Southam CM, Levin AG. Host resistance to cancer. Clinical experiments by homotransplants, autotransplants and admixture of autologous leucocytes. Ann Surg 1965;162:416-25.
6. Gershon RK, Carter RL, Kondo K.Onconcomitant immunity in tumour-bearing hamsters. Nature 1967;213:674-6.
7. Keller R. Repression of lymphatic metastasis by a second implant of the same tumor. Invasion Metastasis 1985;5:295-308. (Pubitemid 15023762)
8. Franco M, Bustuoabad OD, di Gianni PD, Goldman A, Pasqualini CD, Ruggiero RA. A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. Br J Cancer 1996;74:178-86. (Pubitemid 26254127)
9. Sugarbaker EV, Thornthwaite J, Ketcham AS. Inhibitory effect of a primary tumor on metastasis. In:Day SB, Myers W, Stansly P, Garattini S, Lewis M, editors. Cancer invasion and metastasis. Biological mechanisms and therapy. New York: Raven; 1977. p. 227-40.
10. Lange PH, Hekmat K, Bosl G, Kennedy BJ, Fraley EE. Acclerated growth of testicular cancer after cytoreductive surgery. Cancer 1980;45:1498-506. (Pubitemid 10134889)
11. Gorelik E. Antimetastatic concomitant immunity. In:Liotta LA, Hart IR, editors. Tumor invasion and metastasis. The Hague: Martinus Nijhoff Publishers; 1982. p. 113-31.
12. Bonfil RD, Ruggiero RA, Bustuoabad OD, Meiss RP, Pasqualini CD. Role of concomitant resistance in the development of murine lung metastases. Int J Cancer 1988;41:415-22. (Pubitemid 18080798)
13. Di Gianni PD, Franco M, Meiss RP, Vanzulli S, Piazzon I, Pasqualini CD, et al. Inhibition of metastases by a serum factor associated to concomitant resistance induced by unrelated murine tumors. Oncol Rep 1999;6:1073-84.
14. Qadri SS, Wang JH, Coffey JC, Alam M, O'Donnell A, Aherne T, et al. Can surgery for cancer accelerate the progression of secondary tumors within residual minimal disease at both local and systemic levels? Ann Thorac Surg 2005;80:1046-50, discussion 1050-1.
15. Peeters CF, de Waal RM, Wobbes T, Ruers TJ. Metastatic dormancy imposed by the primary tumor: does it exist in humans? Ann Surg Oncol 2008;15:3308-15.
16. Beecken WD, Engl T, Jonas D, Blaheta RA. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy. Int J Mol Med 2009;23:261-6.
17. Tyzzer EE. Factors in the production and growth of tumor metastases. J Med Res 1913;28:309-32.1.
18. Tadenuma K, Okonogi S. Experimentelle Untersuchugen uber Metastasen bei Mausecarcinom. Z Krebsforsch 1924;21:168-72.
19. Ketcham AS, Kinsey DL, Wexler H, Mantel N. The development of spontaneous metastases after the removal of a "primary" tumor. II. Standardization protocol of 5 animal tumors. Cancer 1961;14:875-82.
20. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 1983;39:71-120.
21. Guba M, Cernaianu G, Koehl G, Geissler EK, Jauch KW, Anthuber M, et al.Aprimary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 2001;61:5575-9. (Pubitemid 32694945)
22. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
23. Demicheli R, Retsky MW, Hrushesky WJM, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol 2008;19:1821-8.
24. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995;172:65-72.
25. Demicheli R, Valagussa P, Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer 2001;85:490-2. (Pubitemid 32808269)
26. Retsky MW, Demicheli R, Hrushesky WJM, Baum M, Gukas ID. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 2008;116:730-41.
27. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999;91:80-5. (Pubitemid 29042447)
28. Hoskins WJ. The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:59-71. (Pubitemid 19183094)
29. Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003;4:760-8. (Pubitemid 37527212)
30. Maniwa Y, Kanki M, Okita Y. Importance of the control of lung recurrence soon after surgery of pulmonary metastases. Am J Surg 2000;179:122-5. (Pubitemid 30204514)
31. Mitsudomi T, Nishioka K, Maruyama R, Saitoh G, Hamatake M, Fukuyama Y, et al. Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer. J Surg Oncol 1996;63:159-65. (Pubitemid 26404555)
32. Lacy AM, García-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002;359:2224-9. (Pubitemid 34717975)
33. DeLisser HM, Keirns CC, Clinton EA, Margolis ML. "The air got to it:" exploring a belief about surgery for lung cancer. J Natl Med Assoc 2009;101:765-71.
34. Janik P, Bertram JS, Szaniawska B. Modulation of lung tumor colony formation by a subcutaneously growing tumor. J Natl Cancer Inst 1981;66:1155-8. (Pubitemid 11063915)
35. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008;133:994-1005. (Pubitemid 351787747)
36. Bruzzo J, Chiarella P, Meiss RP, Ruggiero RA. Biphasic effect of a primary tumor on the growth of secondary tumor implants. J Cancer Res Clin Oncol 2010;136:1605-15.
37. North RJ. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 1984;35:89-155. (Pubitemid 14091501)
38. Ruggiero RA, Bustuoabad OD, Bonfil RD, Meiss RP, Pasqualini CD. "Concomitant immunity" in murine tumours of non-detectable immunogenicity. Br J Cancer 1985;51:37-48. (Pubitemid 15151686)
39. Ruggiero RA, Bustuoabad OD, Cramer P, Bonfil RD, Pasqualini CD. Correlation between seric antitumor activity and concomitant resistance in mice bearing nonimmunogenic tumors. Cancer Res 1990;50:7159-65.
40. DeWys WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 1972;32:374-9.
41. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28. (Pubitemid 24324921)
42. Bustuoabad OD, Genovese JA, Pasqualini CD. Abrogation of concomitant tumor immunity in mice. Com Bio 1984;2:423-30.
43. Ruggiero RA, di Gianni PD, Franco M, Bustuoabad OD. Resistencia concomitante antitumoral. Medicina (B Aires) 1996;56(Supl 1):57-64.
44. Franco M, Bustuoabad OD, Di Gianni PD, Meiss RP, Vanzulli S, Buggiano V, et al. Two different types of concomitant resistance induced by murine tumors: morphological aspects and intrinsic mechanisms. Oncol Rep 2000;7:1053-63.
45. Meiss RP, Bonfil RD, Ruggiero RA, Pasqualini CD. Histologic aspects of concomitant resistance induced by nonimmunogenic murine tumors. J Natl Cancer Inst 1986;76:1163-75. (Pubitemid 16093152)
46. Ruggiero RA, Bruzzo J, Chiarella P, di Gianni P, Isturiz MA, Linskens S, et al. Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance. Cancer Res 2011;71:7113-24.
47. Prehn RT. Two competing influences that may explain concomitant tumor resistance. Cancer Res 1993;53:3266-9.
48. Gurer-Orhan H, Ercal N, Mare S, Pennathur S, Orhan H, Heinecke JW. Misincorporation of free m-tyrosine into cellular proteins: a potential cytotoxic mechanism for oxidized amino acids. Biochem J 2006;395:277-84.
49. Bertin C, Weston LA, Huang T, Jander G, Owens T, Meinwald J, et al. Grass roots chemistry: meta-tyrosine, an herbicidal nonprotein amino acid. Proc Natl Acad Sci U S A 2007;104:16964-9. (Pubitemid 350210973)
50. Chiarella P, Vulcano M, Bruzzo J, Vermeulen M, Vanzulli S, Maglioco A, et al. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol Immunother 2008;57:701-18. (Pubitemid 351641031)
51. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008;111:5457-66.
52. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-45. (Pubitemid 41683212)
53. Yu P, Rowley DA, Fu YX, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 2006;18:226-31. (Pubitemid 43327307)
54. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, et al. Resveratrol arrests the cell division cycle atS/G2 phase transition. Biochem Biophys Res Commun 1998;250:53-8. (Pubitemid 28448621)
55. Bilodeau JF, Faure R, Piedboeuf B, Mirault ME. Hyperoxia induces Sphase cell-cycle arrest and p21(Cip1/Waf1)-independent Cdk2 inhibition in human carcinoma T47D-H3 cells. Exp Cell Res 2000;256:347-57. (Pubitemid 30244193)
56. Karnani N, Dutta A. The effect of the intra-S-phase checkpoint on origins of replication in human cells. Genes Dev 2011;25:621-33.
57. Garg R, Callens S, Lim DS, Canman CE, Kastan MB, Xu B. Chromatin association of rad17 is required for an ataxia telangiectasia and rad-related kinase-mediated S-phase checkpoint in response to low-dose ultraviolet radiation. Mol Cancer Res 2004;2:362-9. (Pubitemid 39025299)
58. Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001;276:43221-30.
59. Olivero OA, Tejera AM, Fernández JJ, Taylor BJ, Das S, Divi RL, et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 2005;20:139-46. (Pubitemid 40637814)
60. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
61. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
62. Aznar S, Valerón PF, del Rincón SV, Fernández Pérez L, Perona R, Lacal JC. Simultaneous tyrosine and serine phosphorylation of STAT3 trancription factor is involved in Rho A GTPase oncogenic transformation. Mol Biol Cell 2001;10:3282-94. (Pubitemid 33062979)
63. Yeh YT, Ou-Yang F, Chen IF, Yang SF, Wang YY, Chuang HY, et al. STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int J Cancer 2006;118:2943-7.
64. Jirtle RL, Michalopoulos G. Effects of partial hepatectomy on transplanted hepatocytes. Cancer Res 1982;42:3000-4. (Pubitemid 12041043)
65. Joseph B, Berishvili E, Benten D, Kumaran V, Liponava E, Bhargava K, et al. Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions. Nat Med 2004;10:749-53. (Pubitemid 38937642)
66. Glick AB, Yuspa SH. Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers. Semin Cancer Biol 2005;15:75-83. (Pubitemid 40126238)
67. Ruggiero RA, Bustuoabad OD. The biological sense of cancer: a hypothesis. Theor Biol Med Model 2006;3:43.
68. El Saghir NS, Elhajj II, Geara FB, Hourani MH. Trauma-associated growth of suspected dormant micrometastasis. BMC Cancer 2005;5:94.
69. Ossowski L, Aguirre-Ghiso JA. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010;23:41-56.